Scott Hammer

2.9k total citations
23 papers, 1.6k citations indexed

About

Scott Hammer is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Scott Hammer has authored 23 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 17 papers in Virology and 5 papers in Epidemiology. Recurrent topics in Scott Hammer's work include HIV Research and Treatment (17 papers), HIV/AIDS drug development and treatment (14 papers) and HIV/AIDS Research and Interventions (13 papers). Scott Hammer is often cited by papers focused on HIV Research and Treatment (17 papers), HIV/AIDS drug development and treatment (14 papers) and HIV/AIDS Research and Interventions (13 papers). Scott Hammer collaborates with scholars based in United States, Canada and Thailand. Scott Hammer's co-authors include Matthew H. Samore, Sotirios Tsiodras, Christos S. Mantzoros, Nicole Ngo‐Giang‐Huong, Pacharee Kantipong, Chureeratana Bowonwatanuwong, Marc Lallemant, Gonzague Jourdain, Sophie Le Cœur and Pranee Leechanachai and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Journal of Clinical Microbiology.

In The Last Decade

Scott Hammer

22 papers receiving 1.6k citations

Peers

Countries citing papers authored by Scott Hammer

Since Specialization

Citations

This map shows the geographic impact of Scott Hammer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Hammer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Hammer more than expected).

Fields of papers citing papers by Scott Hammer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Hammer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Hammer. The network helps show where Scott Hammer may publish in the future.

Co-authorship network of co-authors of Scott Hammer

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Hammer. A scholar is included among the top collaborators of Scott Hammer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Hammer. Scott Hammer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy 2016 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Catherine Vaughan, Yeycy Donastorg, Scott Hammer, Karen Brudney, Barbara S. Taylor	26
2	CD8 ⁺ T-cell Mediated HIV Inhibition after Vaccination with a DNA/Recombinant Ad5 (rAd5) HIV Vaccine Is Similar to that Seen in Treated HIV Infection 2014 ·AIDS Research and Human Retroviruses ·Nicole Frahm, (unknown), Stephen C. De Rosa, Christina Ochsenbauer, Shelly Karuna, Magdalena E. Sobieszczyk, Scott Hammer, Edith Swann, Barney S. Graham, Peter B. Gilbert, (unknown), (unknown)	1
3	Comparing Interferon-Gamma Release Assays to Tuberculin Skin Test in Thai Children with Tuberculosis Exposure 2014 ·PLoS ONE ·Hong‐Van Tieu, Piyarat Suntarattiwong, Thanyawee Puthanakit, Tawee Chotpitayasunondh, Kulkanya Chokephaibulkit, Sunee Sirivichayakul, Supranee Buranapraditkun, (unknown), Nitiya Chomchey, Simon Tsiouris, Scott Hammer, Vijay Nandi, Jintanat Ananworanich, (unknown)	12
4	Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jonathan D. Fuchs, Magdalena E. Sobieszczyk, Tamra Madenwald, Doug Grove, Shelly Karuna, Michele P. Andrasik, Adam Sherwat, Gail Broder, Kenneth H. Mayer, Beryl A. Koblin, Scott Hammer	15
5	Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase 2012 ·PLoS ONE ·Jessica H. Brehm, (unknown), Dianna Koontz, (unknown), Scott Hammer, David Katzenstein, John W. Mellors, Nicolas Sluis‐Cremer	7
6	Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience 2008 ·HIV Clinical Trials ·Lisa M. Demeter, Victor DeGruttola, Stephanie Lustgarten, (unknown), Margaret A. Fischl, Susan H. Eshleman, William Spreen, Bach-Yen Nguyen, Christine Koval, Joseph J. Eron, Scott Hammer, Kathleen Squires	13
7	Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data 2008 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), Julio Montaner, P. Richard Harrigan, Brian Gazzard, Anton Pozniak, Michael D. Miller, Sean Emery, Frank van Leth, Patrick Robinson, John D. Baxter, (unknown), Delivette Castor, Scott Hammer, Alex R. Rinehart, Hans Vermeiren, Elke Van Craenenbroeck, Lee T. Bacheler	28
8	Changes in Hepatitis C Virus (HCV) Viral Load and Interferon-α Levels in HIV/HCV-Coinfected Patients Treated With Highly Active Antiretroviral Therapy 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·William A. Bower, David H. Culver, Delivette Castor, Yingfeng Wu, (unknown), (unknown), Scott Hammer, Wendi L. Kuhnert, Ian T. Williams, Beth P. Bell, David Vlahov, Charlene S. Dezzutti	11
9	Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission 2006 ·AIDS ·Shayne Loubser, Peter Balfe, Gayle Sherman, Scott Hammer, Louise Kuhn, Lynn Morris	87
10	Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis 2005 ·Journal of Clinical Microbiology ·Sarah Palmer, Mary F. Kearney, Frank Maldarelli, Elias K. Halvas, (unknown), Holly Bazmi, (unknown), Judith Falloon, Richard T. Davey, Robin Dewar, Julia A. Metcalf, Scott Hammer, John W. Mellors, John M. Coffin	390
11	Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy 2004 ·New England Journal of Medicine ·Gonzague Jourdain, Nicole Ngo‐Giang‐Huong, Sophie Le Cœur, Chureeratana Bowonwatanuwong, Pacharee Kantipong, Pranee Leechanachai, (unknown), Prattana Leenasirimakul, Scott Hammer, Marc Lallemant	302
12	The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society. 2002 ·PubMed ·Diane V. Havlir, Stefano Vella, Scott Hammer	4
13	ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results 2001 ·AIDS ·Robert L. Murphy, Scott Brun, Charles B. Hicks, Joseph J. Eron, Roy M. Gulick, Martin King, A. Clinton White, Constance A. Benson, Melanie Thompson, Harold A. Kessler, Scott Hammer, Richard Bertz, Ann Hsu, Anthony J. Japour, Eugene Sun	187
14	Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and Lipodystrophy 2000 ·Archives of Internal Medicine ·Sotirios Tsiodras, Christos S. Mantzoros, Scott Hammer, Matthew H. Samore	356
15	Comparison of Gynecologic History and Laboratory Results in HIV-Positive Women With CD4+ Lymphocyte Counts Between 200 and 500 Cells/μl and Below 100 Cells/μl 1999 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·D. Heather Watts, Cathie Spino, Lawrence Zaborski, David Katzenstein, Scott Hammer, Constance A. Benson	12
16	Use of Surrogate Versus Clinical Markers in Trials for HIV Infection 1999 ·Drug Information Journal ·Scott Hammer	1
17	Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120 1998 ·AIDS Research and Human Retroviruses ·Lisa A. Cavacini, Matthew H. Samore, John G. Gambertoglio, J. Brooks Jackson, Mark Duval, Adam V. Wisnewski, Scott Hammer, (unknown), Carol Braun Trapnell, Marshall R. Posner	49
18	The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker 1998 ·AIDS ·Helen Kastrissios, (unknown), Scott Hammer, David Katzenstein, Terrence F. Blaschke	54
19	Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1* 1996 ·Clinical Pharmacology & Therapeutics ·Erika J. Wolfe, Lisa A. Cavacini, Matthew H. Samore, Marshall R. Posner, (unknown), Cathie Spino, Carol Braun Trapnell, Nzeera Ketter, Scott Hammer, John G. Gambertoglio	21
20	Antiretroviral and immune-based therapies 1993 ·AIDS ·Patrick Yéni, Robert T. Schooley, Scott Hammer	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact